2011 Fiscal Year Final Research Report
New strategy of intravesical in stillation using anti-cancer peptide for bladder tumor
Project/Area Number |
21592031
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Urology
|
Research Institution | University of Tsukuba |
Principal Investigator |
SHIMAZUI Toru 筑波大学, 医学医療系, 教授 (80235613)
|
Co-Investigator(Kenkyū-buntansha) |
UCHIDA Kazuhiko 筑波大学, 医学医療系, 准教授 (90211078)
|
Co-Investigator(Renkei-kenkyūsha) |
YOSHIKAWA Kazuhiro 愛知医科大学, 医学部, 准教授 (60109759)
|
Project Period (FY) |
2009 – 2011
|
Keywords | 腫瘍学 |
Research Abstract |
P16, which is a key molecule of bladder tumor (BT) development, inhibits the tumor growth through maintaining the retinoblastoma protein (Rb) in its hypophosphorylated state. In clinical samples, it is reported that abnormal p16 was observed in approximately 70% of human BT. In this study, we investigated whether or not new peptide transporter system using Wr-T with minimum inhibitory sequence peptide of p16 (p16-MIS) could inhibit growth of BT. In vitro, peptide transfer with p16-MIS successfully inhibit the human and mouse bladder tumor cell line with absent p16 and phosphorylated Rb. In the in vivo study, both local and systemic administration of p16-MIS using Wr-T system inhibited the growth of subcutaneous BT graft in mice. In histological examination, p16-MIS transfer decreased the Rb phosphorylation and induced the apoptosis. Although animal model for intravesical transplantation of BT should be established, peptide transporter with p16-MIS and Wr-T might become a possible new treatment strategy by intravesical instillation.
|
Research Products
(10 results)